Vanguard Asset Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Vanguard Asset Management's AXSM Position: Q3 2026 in Review
Vanguard Asset Management increased its Axsome Therapeutics (AXSM) stake by 11% in Q3 2026, buying an estimated $929K and bringing the position to 42,880 shares worth $7.91M. The position accounts for ﹤0.01% of the portfolio, ranked #816.
Vanguard Asset Management first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $9.45M in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Vanguard Asset Management held 42,880 shares of Axsome Therapeutics worth $7.91M as of Q3 2026.
- Vanguard Asset Management bought 4,270 Axsome Therapeutics shares in Q3 2026, an estimated $929K.
- Axsome Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #816 holding.
- Vanguard Asset Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Axsome Therapeutics position peaked at $9.45M in Q2 2026.
- 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.